UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

Breast cancer research and treatment, 2011-04, Vol.126 (2), p.453-461

2011

Volltextzugriff (PDF)

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Annals of oncology, 2008-05, Vol.19 (5), p.877-882

2008

Volltextzugriff (PDF)

Quality of Life Scores: An Independent Prognostic Variable in a General Population of Cancer Patients Receiving Chemotherapy

Quality of life research, 1997-03, Vol.6 (2), p.151-158

1997

Volltextzugriff (PDF)

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer

Annals of oncology, 2006-11, Vol.17 (11), p.1637-1643

2006

Volltextzugriff (PDF)

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

The Lancet (British edition), 1993-07, Vol.342 (8862), p.19-21

1993

Volltextzugriff (PDF)

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease

Journal of clinical oncology, 1998-03, Vol.16 (3), p.818-829

1998

Volltextzugriff (PDF)

Comparing the predictive value of neural network models to logistic regression models on the risk of death for small-cell lung cancer patients

European journal of cancer care, 2006-05, Vol.15 (2), p.115-124

2006

Volltextzugriff (PDF)

The economic impact of the transition from branded to generic oncology drugs

Current oncology (Toronto), 2019-04, Vol.26 (2), p.89-93

2019

Volltextzugriff (PDF)

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy

Journal of clinical oncology, 1997-08, Vol.15 (8), p.2966-2973

1997

Volltextzugriff (PDF)

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer

Journal of clinical oncology, 1993-02, Vol.11 (2), p.336-344

1993

Volltextzugriff (PDF)

Linkage of clinical trial and administrative data: a survey of cancer patient preferences

Current oncology (Toronto), 2017-06, Vol.24 (3), p.161-167

2017

Volltextzugriff (PDF)

A Validation Study of the Domains of the Core EORTC Quality of Life Questionnaire

Quality of life research, 1993-10, Vol.2 (5), p.319-325

1993

Volltextzugriff (PDF)

Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada

Current oncology (Toronto), 2016-02, Vol.23 (Suppl 1), p.S7-13

2016

Volltextzugriff (PDF)

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

Journal of clinical oncology, 1988-04, Vol.6 (4), p.633-641

1988

Volltextzugriff (PDF)

Second primary malignancies following the treatment of early stage ovarian cancer: Update of a study by the National Cancer Institute of Canada—Clinical Trials Group (NCIC—CTG)

Annals of oncology, 2000-01, Vol.11 (1), p.65-68

2000

Volltextzugriff (PDF)

Fatigue in patients with cancer : results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30

Supportive care in cancer, 1997-09, Vol.5 (5), p.410-413

1997

Volltextzugriff (PDF)

Funding New Cancer Drugs in Ontario: Closing the Loop in the Practice Guidelines Development Cycle

Journal of clinical oncology, 2001-07, Vol.19 (14), p.3392-3396

2001

Volltextzugriff (PDF)

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Annals of oncology, 1997-02, Vol.8 (2), p.181-185

1997

Volltextzugriff (PDF)

Priority-setting decisions for new cancer drugs: a qualitative case study

The Lancet (British edition), 2001-11, Vol.358 (9294), p.1676-1681

2001

Volltextzugriff (PDF)

Research on Health-Related Quality of Life: Dissemination into Practical Applications

Quality of life research, 1994-08, Vol.3 (4), p.279-283

1994

Volltextzugriff (PDF)

Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer

Journal of clinical oncology, 1993-06, Vol.11 (6), p.1156-1164

1993

Volltextzugriff (PDF)

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 1991-05, Vol.9 (5), p.729-735

1991

Volltextzugriff (PDF)

Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging

Gynecologic oncology, 1991-12, Vol.43 (3), p.195-197

1991

Volltextzugriff (PDF)

Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method

Medicine (Baltimore), 2001-01, Vol.80 (1), p.45-53

2001

Volltextzugriff (PDF)

Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models

Clinical cancer research, 2003-09, Vol.9 (11), p.4227-4239

2003

Volltextzugriff (PDF)

1 – 25 von 537

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(463)
Mit Volltextzugriff
(468)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Quality of Life Scores: An Independent Prognostic Variable in a General Population of Cancer Patients Receiving Chemotherapy

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease

Comparing the predictive value of neural network models to logistic regression models on the risk of death for small-cell lung cancer patients

The economic impact of the transition from branded to generic oncology drugs

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer

Linkage of clinical trial and administrative data: a survey of cancer patient preferences

A Validation Study of the Domains of the Core EORTC Quality of Life Questionnaire

Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

Second primary malignancies following the treatment of early stage ovarian cancer: Update of a study by the National Cancer Institute of Canada—Clinical Trials Group (NCIC—CTG)

Fatigue in patients with cancer : results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30

Funding New Cancer Drugs in Ontario: Closing the Loop in the Practice Guidelines Development Cycle

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Priority-setting decisions for new cancer drugs: a qualitative case study

Research on Health-Related Quality of Life: Dissemination into Practical Applications

Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging

Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method

Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models

Suchergebnisse filtern